ProCE Banner Activity

MPNSG-0212: Ruxolitinib + Pomalidomide Clinically Active and Well Tolerated in MF

Slideset Download
Conference Coverage
A combination of ruxolitinib + pomalidomide showed reduction of splenomegaly and improvement of cytopenia in some patients with pretreated and high-risk MF.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen